This invention relates to the application of hydroxyapatite chromatography to the purification of at least one antibody from a preparation containing high molecular weight aggregates. Further, this invention relates to an integration of ceramic hydroxyapatite chromatography into a combination chromatographic protocol for the removal of high molecular weight aggregates from an antibody preparation.

Materials and methods for mitigating the effects of halide species contained in process streams are provided. A halide-containing process stream can be contacted with mitigation materials comprising active metal oxides and a non-acidic high surface area carrier combined with a solid, porous substrate. The halide species in the process stream can be reacted with the mitigation material to produce neutralized halide salts and a process stream that is essentially halide-free. The neutralized salts can be attracted and retained on the solid, porous substrate.

An object of the invention is to provide a treatment agent for treating excrement and the like. The treatment agent is an aggregated treatment agent comprising slaked lime, a water absorptive polymer, a binder, and at least one member selected from the group consisting of a phosphoric acid salt, a carbonic acid salt and a hydroxide at pH 8 to 13.

Methods and compositions are provided for treatment of an apatite-based resin from which retained solutes have been eluted by an elution buffer that contains an alkali metal salt with solutions of calcium ion, phosphate ion, and hydroxide separately from any sample loading and elution buffers. The treatment solutions restore the resin, reversing the deterioration that is caused by the alkali metal salt in the elution buffer.

The present invention provides that powder is mainly constituted from secondary particles of hydroxyapatite. The secondary particles are obtained by drying a slurry containing primary particles of hydroxyapatite and aggregates thereof and granulating the primary particles and the aggregates. A bulk density of the powder is 0.65 g/mL or more and a specific surface area of the secondary particles is 70 m.sup.2/g or more. The powder of the present invention has high strength and is capable of exhibiting superior adsorption capability when it is used for an adsorbent an adsorption apparatus has.

The disclosure relates to systems and methods for generating a brine solution using a salt cartridge for recharging zirconium phosphate in a reusable sorbent module. The salt cartridge can include an inlet and an outlet on opposite sides. Water can be pumped through the salt cartridge to dissolve the salts in the salt cartridge and the resulting solution can be collected as a brine solution for use in recharging the zirconium phosphate.

A deodorant composition may be suitable for use with an aldehyde gas or a ketone gas, and may include an aminoguanidine salt and a metal chelating agent. The aminoguanidine salt is preferably at least one of an aminoguanidine hydrochloride and an aminoguanidine sulfate. The chelating agent is preferably at least one of an inorganic phosphoric acid and salt thereof, and a carboxylic acid and salt thereof.

A moisture absorbent for a vehicle lamp includes a first inorganic material, a second inorganic material, alkali metal phosphate, and a polymer wax are included. A composite moisture absorbent structure includes a first moisture absorbent pack including a powder type moisture absorbent and a second moisture absorbent pack including a capsule type moisture absorbent are embedded.

The present invention relates to a hydroxyapatite and/or tricalcium phosphate powder characterized in that it has undergone at least one sintering step at a temperature between 400° C. and 600° C. The invention also relates to a process for preparing such a powder, and to a composition comprising such a powder for use as an anti-tumour auto-vaccine and particularly in the treatment of the following pathological conditions: osteosarcoma, B or T lymphoma, mammary tumour, melanoma, haemangiosarcoma, mastocytoma, fibrosarcoma, brain tumours and schwannoma in a subject. The present invention also covers a drug combination comprising the composition of the invention and at least one second therapeutic agent, preferably an anti-tumour agent and/or a radiotherapeutic agent.

A method of preparing a universal blood product comprising obtaining a blood product; contacting the blood product with (i) hydroxyapatite; (ii) a carbonaceous material comprising at least a mixture of a first carbon particle having macroporous size α and a second carbon particle having macroporous size β; and (iii) at least one support matrix chemically associated with an antigenic determinant.to form a cleansed product; and recovering the cleansed product.